Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer [Thoracic Oncology]

Conclusion
%SUVremaining is a predictor for survival and other end points after multimodality treatment and can serve as a parameter for treatment stratification after induction chemotherapy or for evaluation of adjuvant new systemic treatment options for high-risk patients.

Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Pottgen, Gauler, Bellendorf, Guberina, Bockisch, Schwenzer, Heinzelmann, Cordes, Schuler, Welter, Stamatis, Friedel, Darwiche, Jockel, Eberhardt, Stuschke Tags: Combined Modality, Nuclear Medicine Thoracic Oncology Source Type: research